Abstract
Hodgkin lymphoma, formerly known as Hodgkin disease, has gone from an incurable disease to one with a cure rate of almost 75% . The disease is defined in terms of its (1) microscopic appearance (histology) and the e x p re s s i o n o f c e l l s u r f a c e m a r ke r s (immunophenotype), but its biologic behavior and clinical characteristics are also important.
In classical Hodgkin lymphoma (cHL), the neoplastic cell is the Hodgkin-ReedSternberg cell (HRS) . Reed-Sternberg cells (2, 3) comprise only 1-2% of the total tumor cell mass ( Figure 1 ( H S C T ) a n d p o s t t r a n s p l a n t a t i o n 
Single-agent salvage therapy is given as follows:
l Brentuximab vedotin, 1.8 mg/kg once and chemotherapy or brentuximab (10, 11, 12, 13) vedotin plus immunotherapy (nivolumab) , (14) with preliminary data showing high response rates. To date, there are no randomized trials to establish a standard pre-transplant regimen. In the frontline setting, the combination of nivolumab followed by nivolumab plus AVD (A -doxorubicin (Adriamycin), V -vinblastine, D -dacarbazine)
is being studied in patients with advancedstage disease ,with promising early results. (15) Finally, an emerging area of research is the use of chimeric antigen receptor (CAR) T-cells to treat Hodgkin lymphoma. This will be an ongoing area of investigation . (16) The current treatment of Hodgkin lymphoma seeks to maximize the risk-benefit ratio of treatment.
Thus, treatment focuses on tailoring therapy to each patient according to age, risk of shortterm and long-term toxicity, and risk of relapse.
